


All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan



AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA142)

NICE GUIDANCE ISSUED MAY 2008

(Refer to NICE website for full guidance on NICE recommendations,
including any specific restrictions on the use of the technology)

Epoetin beta (NeoRecormon[®])

**For the treatment of symptomatic anaemia in adult
patients with non-myeloid malignancies receiving
chemotherapy**

Roche Products Ltd

March 2004

Epoetin beta (NeoRecormon[®]) is indicated for the treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.

AWMSG appraised epoetin beta (NeoRecormon[®]) during the December 2003 meeting and the decision was not to support the use of erythropoietin in the treatment of anaemia associated with cancer due to the lack of evidence of cost-effectiveness.

[See AWMSG December 2003 meeting minutes for further information.](#)